BIOCON LTD. - 532523 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kiran Mazumdar Shaw & Others BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Meetings
Bengaluru rain havoc: Devastating, says Kiran Mazumdar-Shaw
Both the government and developers need to take collective responsibility to address water-logging, the Executive Chairperson of Bengaluru-headquartered biopharmaceuticals company, Biocon, told PTI on Tuesday. BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor meeting
Biocon sheds 4%, hits 52-week low as US FDA issues form 483 for 3 sites
The US health regulator has issued Form 483s with 11 observations each for two sites in Bengaluru and six observations for a plant in Malaysia site. US FDA issues 11 observations each for two sites in Bengaluru: Biocon
Biocon Ltd on Wednesday said the US health regulator has issued Form 483s with 11 observations each for two sites in Bengaluru and six observations for a plant in Malaysia, following inspection of seven manufacturing facilities of its arm Biocon Biologics. As per US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The USFDA conducted three on-site inspections of Biocon Biologics' seven manufacturing facilities spanning two sites in Bengaluru, India and one at Johor, Malaysia, Biocon said in a regulatory filing. The inspections started with the Bengaluru site on August 11, 2022 and concluded with the Malaysia site on August 30, 2022, it added. "At the conclusion of these inspections, the agency has issued Form 483s with 11 observations each for the two sites in Bengaluru and six . BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor meeting CBI files charge sheet in Rs 9 lakh Biocon Biologics bribery case
The CBI has filed a charge sheet in an alleged bribery case in which a senior official of the Central Drugs Standard Control Organisation(CDSCO) and a Biocon Biologics executive were arrested in June this year, officials said It is alleged that the bribe payment of Rs nine lakh to Joint Drug Controller S Eswara Reddy was cleared by the associate vice president of Biocon Biologics L Praveen Kumar, they said. The bribe was allegedly for favourably recommending the file of Insulin Aspart Injection to the Subject Expert Committee (SEC) meeting on May 18 for waiving the phase 3 clinical trial, they said. The agency had filed a charge sheet on August 18, they said. In a coordinated operation, the CBI had arrested Reddy, Kumar, Dinesh Dua, director at Synergy Network India Private Limited, who allegedly gave the bribe to Reddy, Guljit Sethi, an alleged conduit of Biocon Biologics, as well as assistant drug inspector Animesh Kumar in the case. Biocon Biologics, a subsidiary of Kiran Mazum BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investors meeting